An experimental gene therapy known as AMT-130 has become the first treatment to successfully slow the progression of Huntington’s disease, marking a potential breakthrough in the fight against neurodegenerative disorders. As shared in Newscientist, the therapy, developed by the Dutch biotech company uniQure, works by targeting the mutant huntingtin protein responsible for the disease’s devastating effects on the brain.

How It Works

AMT-130 uses a harmless virus to deliver genetic material into brain cells. This material instructs cells to produce microRNA, a small molecule that intercepts and disables the genetic instructions for producing the toxic huntingtin protein. The therapy is administered via a single injection into two deep brain regions (the caudate nucleus and putamen) using real-time imaging to guide the procedure, which lasts 12 to 18 hours.

Promising Results

In a clinical trial led by University College London, 17 participants received a high dose of AMT-130. Over three years, their disease progression slowed by approximately 75% compared to untreated individuals. Cognitive and motor declines that typically occur in one year were delayed to four years. Additionally, treated patients showed reduced levels of a brain damage marker in their cerebrospinal fluid.

Safety and Outlook

So far, the therapy appears safe and well-tolerated, with mild side effects such as headaches and confusion, which resolved naturally or with steroids. uniQure plans to submit the therapy for FDA approval in early 2026, with potential availability by 2027.

Broader Implications

Experts believe this approach could pave the way for similar treatments targeting other neurodegenerative diseases, including Parkinson’s and Alzheimer’s, by modifying the genetic material to target different toxic proteins.

While more research is needed to confirm long-term safety and efficacy, AMT-130 represents a significant step forward in gene-based therapies for brain disorders.